May 2017: The Antibody Update

In the May Antibody Update, you can expect to find news of an enzyme inhibitor that increases the efficacy of anti-PD-1 Immunotherapy, the generation of induced pluripotent blood stem cells, and the rapid employment of the latest Ebola vaccine in the Democratic Republic of the Congo. Learn more at ProSci.

February 2017: The Antibody Update

This month's Antibody Update includes news on how your skin bacteria regulate levels of Staphylococus aureus, a new study using single cell sequence analysis to create 3D models of tumor tissue, and development of chimeric antigen receptor T-cells using CRISPR/Cas9 to enhance immunotherapy.

Problems with Immunotherapy

Immune system checkpoint inhibition may not always be the perfect way to target cancer. Why is it that some patients do not respond positively to certain immunotherapy treatments like Ipilimumab? This blog takes into account the immune system's convoluted nature to understand how immune checkpoint antibodies may not be the problem, and how personalized medicine could help.

T-cell Activation: The Purpose of CD28, CTLA-4, and CD80/CD86 

Cancer immunotherapy involves targeting receptors and ligands of T-cells and tumor cells to amplify an immune response. By targeting these receptors and ligands, T-cell anti-cancer activity can be regulated. This blog explains how the receptors CD28 and CTLA-4 and their ligands CD80 and CD86 are involved in T-cell activation and inhibition. Take a look!

December 2016: The Antibody Update

ProSci's last Antibody Update of 2016 includes the super effective Ebola vaccine developed by Merck, using the common diabetes drug metformin and the antihypertensive syrosingopine to combat cancer, and a link to a highlight review of the immune checkpoint TIGIT. Check it out!

November 2016: The Antibody Update

This months Antibody Update features the first use of CRISPR-Cas9 modified cells being used as therapeutics, the launch of the first vaccine against malaria, and the 21st Century Cures act, which may vastly increase funding of public health agencies for the next decade. Learn more here.

October 2016: The Antibody Update

The October 2016 Antibody Update includes news on a successful combination immunotherapy for cancer, the story of the Yoshinori Ohsumi's Nobel Prize in Medicine, the release of bacterially infected mosquitoes in Brazil to combat the spread of Zika virus, and a reminder to come looking for ProSci at SfN 2016. Get a look at the October's big news round-up here!

June 2016: The Antibdy Update

This Antibody Update's news includes the first CRISPR/Cas9 cancer therapeutic's entry into clinical trials, how mosquito saliva assists viruses in proliferation, and the latest update on antibody validation. Check it out on ProSci's blog.

March 2016: The Antibody Update

This month's Antibody Update covers a possible vaccine for Dengue, a new HIV antibody, and the effects of pH on immune cell activity in tumors. Also announcing the launch of Rabbit Monoclonal Antibody Services!

Curing Cancer

ProSci would like to update you on how immunotherapy is being leveraged to battle cancer. Immunotherapy is the heart of multiple, promising cancer treatments in 2016. These treatments aim to harnesses the power of our highly sophisticated immune systems through immune checkpoint inhibitors, genetic modification of T cells, and manipulation of cytokine concentrations.